Akari Therapeutics, Plc announced on November 19, 2024, that it received written notice from The Nasdaq Stock Market LLC confirming the cure of its deficiency under Listing Rule 5550(b). This means the company is now in full compliance with all Nasdaq continued listing requirements.
The deficiency was related to the company's shareholder equity. The successful completion of the merger with Peak Bio, Inc. and the associated financing contributed to resolving this issue.
Regaining full compliance removes the risk of delisting from Nasdaq, ensuring Akari's continued presence on a major U.S. stock exchange. This development provides stability and confidence for investors regarding the company's listing status.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.